Efficacy and safety of fezakinumab (an anti-IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments - A randomized, double-blind, phase 2a trial.
| Author | |
|---|---|
| Abstract |
:
IL-22 promotes epidermal hyperplasia and inhibits skin barrier function. |
| Year of Publication |
:
2018
|
| Journal |
:
Journal of the American Academy of Dermatology
|
| Date Published |
:
2018
|
| ISSN Number |
:
0190-9622
|
| URL |
:
http://linkinghub.elsevier.com/retrieve/pii/S0190-9622(18)30101-4
|
| DOI |
:
10.1016/j.jaad.2018.01.016
|
| Short Title |
:
J Am Acad Dermatol
|
| Download citation |
